Clinical Trials

21 enrolled

Stomach Neoplasms

NCT05671900 2024-03-08

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Phase NA Unknown

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

120 enrolled

Prostatic Neoplasms

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

48 enrolled

Nasopharyngeal Carcinoma

NCT02465736 2024-01-16

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

610 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03646968 2023-12-27

SAVE

43 enrolled

Non-Squamous Non Small Cell Lung Cancer

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05262335 2023-11-28

ALTER-G-001

116 enrolled

Digestive System Neoplasms

NCT06107114 2023-11-22

CZCNRHNSCC

52 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04999332 2023-11-15

LOTS

58 enrolled

Stomach Neoplasms

NCT03926091 2023-11-14

CLOVER

2,172 enrolled

Breast Neoplasms

NCT06130007 2023-11-13

B2023-153

48 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06023875 2023-09-05

NCCCNRHNSCC

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

51 enrolled

Hypopharyngeal Neoplasms

NCT02679040 2023-07-03

HIST-RIC

101 enrolled

Breast Neoplasms

NCT02760667 2023-06-27

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

20 enrolled

Head and Neck Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT05914753 2023-06-22

Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Phase NA Unknown

200 enrolled

Breast Neoplasms

NCT04819971 2023-04-25

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

67 enrolled

Stomach Neoplasms

NCT04139772 2023-03-24

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

18 enrolled

Metastatic Castration-resistent Prostate Cancer

NCT05769725 2023-03-15

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

70 enrolled

Stomach Neoplasms

NCT02099175 2023-03-13

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

41 enrolled

Sinonasal Tumors

NCT02099188 2023-03-13

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

27 enrolled

Unresectable Sinonasal Tumors

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT03240835 2023-01-31

The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients

Unknown

50 enrolled

Nasopharyngeal Carcinoma, Malnutrition

NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

75 enrolled

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

NCT05656079 2022-12-19

easy laugh

Phase NA Unknown

204 enrolled

Breast Neoplasms

NCT05611463 2022-11-10

CHANCE

25 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

135 enrolled

Prostatic Neoplasms

NCT05461261 2022-10-24

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

50 enrolled

Hormone Sensitive Metastatic Prostate Cancer

NCT05483439 2022-08-05

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

100 enrolled

Breast Neoplasms

NCT05400993 2022-06-06

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

59 enrolled

Breast Neoplasms

NCT03001726 2022-05-06

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

Unknown

228 enrolled

Stomach Neoplasms

NCT04878107 2022-05-02

SABRE

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

35 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05322499 2022-04-11

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT03061643 2022-03-08

An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

42 enrolled

Prostatic Neoplasms

NCT05251766 2022-02-23

Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

Phase 1 Unknown

30 enrolled

Breast Neoplasms

NCT05253066 2022-02-23

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

130 enrolled

Breast Neoplasms

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

190 enrolled

HER2-positive Breast Cancer

NCT03238495 2021-12-07

HERMET

100 enrolled

HER2-positive Breast Cancer

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT04367909 2021-11-08

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

68 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT02512315 2021-08-30

A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma

192 enrolled

Nasopharyngeal Carcinoma

NCT03119857 2021-08-18

Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14

349 enrolled

Prostatic Neoplasms

NCT05008237 2021-08-17

Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

42 enrolled

Salivary Gland Neoplasms

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

60 enrolled

Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)